Table 3:

Factors impacting branch vessel patency—entire cohorta

Patent Branch VesselOccluded Branch VesselUnivariate P ValueMultivariate P ValueOR (95% CI)
Mean patient age (yr)54.4 ± 12.259.3 ± 10.2.04.1791.03 (0.99–1.07)
Male26 (13.8%)4 (13.8%).996
Acutely ruptured target lesion7/188 (3.7%)1/29 (3%).942
Mean max aneurysm sac size5.6 ± 3.84.2 ± 2.3.067.1170.87 (0.73–1.04)
Mean aneurysm neck size3.4 ± 1.73.0 ± 1.2.139
Mean procedural time (min)206 ± 66214 ± 60.513
Mean fluoroscopy time (min)64 ± 3662 ± 27.764
>1 PED deployed17/188 (9.0%)1/29 (3.4%).309
% PED classic107/125 (86%)18/29 (62.1%).601
Balloon angioplasty13/188 (7%)1/29 (7%).479
Mean PED diameter (mm)4.0 ± 0.53.5 ± 0.5<0.001.0010.16 (0.06–0.45)
Mean Δmax size of parent vessel and PED0.22 ± 0.190.26 ± 0.26.405
Mean Δmin size of parent vessel and PED0.77 ± 0.410.67 ± 0.40.230
Branch vessel incorporation into aneurysm sac52/188 (28%)9/29 (31%).707
Mean periprocedural P2Y12127 ± 68122 ± 80.379
Intraprocedural administration of abciximab17/188 (9.0%)3/29 (10.3%).821
Presence of endothelial hyperplasia43/185 (23%)10/29 (34%).192
Mean length of DSA follow-up (mo)18.3 ± 9.920.1 ± 8.8.351
A1 ACA7/11 (63.6%)4/11 (36.3%).021.8131.29 (0.16–10.56)
Anterior choroidal artery30/31 (96.8%)1/31 (3.2%).073.0920.10 (0.01–1.46)
PcomA26/39 (66.6%)13/39 (33.3%)<.001.2053.26 (0.52–20.28)
Ophthalmic artery118/125 (94%)8/125 (6%)<.0010.4490.49 (0.08–3.07)
  • Note:—ACA indicates anterior cerebral artery; max, maximum; min, minimum; PcomA, posterior communicating artery.

  • a Percentages reflect analysis per branch vessel.